Original Article URI1 Amplification in Uterine Carcinosarcoma Associates with Chemo-Resistance and Poor Prognosis

Total Page:16

File Type:pdf, Size:1020Kb

Original Article URI1 Amplification in Uterine Carcinosarcoma Associates with Chemo-Resistance and Poor Prognosis Am J Cancer Res 2015;5(7):2320-2329 www.ajcr.us /ISSN:2156-6976/ajcr0010111 Original Article URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis Yu Wang1,2, Michael J Garabedian2, Susan K Logan1,3 Departments of 1Urology, 2Microbiology, 3Biochemistry and Molecular Pharmacology, New York University School of Medicine, 550 First Avenue, MSB235, New York, NY 10016, USA Received May 11, 2015; Accepted June 11, 2015; Epub June 15, 2015; Published July 1, 2015 Abstract: Uterine carcinosarcoma (UCS) is a rare type of cancer and accounts for 5% of uterine malignancies. However, UCS patients suffer a high prevalence of chemo-resistance and a very poor prognosis compared to uterine cancer patients. URI is a chaperone with functions in transcription. We analyzed the somatic URI1 copy number variation in 57 post-menopausal non-metastatic UCS patients in comparison to 363 uterine corpus endometrial carcinomas. URI1 amplification was detected in 40% (23/57) of primary UCS and 5.5% (20/363) of uterine carci- nomas. UCS patients with URI1 amplification exhibited 13% (3/23) tumor-free survival compared to 41% (14/34) in the absence of URI amplification (P=0.023).URI1 amplification (OR=6.54, P=0.027), weight (OR=1.068, P=0.024), hypertension (OR=3.35, P=0.044), and tumor stage (OR=2.358, P=0.018) associated with poor survival. Patients treated with hormone replacement therapy (OR=15.87, P=0.011) displayed enhanced overall survival. Combined radiation and chemotherapy improved patient survival (median survival=2043 days) compared to single (median survival=597 days) or no treatment (median survival=317 days, P=0.0016). Importantly, patients with URI1 amplifi- cation had poor response to adjuvant treatment compared to control group (P=0.013). Tumors with URI1 amplifica- tion displayed decreased transcription of genes encoding tumor suppressor and apoptotic regulators and increased expression of genes regulating oncogenesis, survival and metastasis. Overexpression of URI1 in a cultured cell model induced ATM expression and resistance to cisplatin. Our findings suggest that high prevalence in UCS may associate with poor prognosis and worse response to adjuvant treatment. Keywords: URI1, uterine carcinosarcoma, prognosis, survival Introduction tives or postmenopausal hormone therapy reduces the risk of both types of cancers [10- Uterine carcinosarcoma (UCS), also known as 13]. The primary management of UCS is surgi- malignant mixed Mullerian tumor (MMMT), is cal, although adjuvant radiotherapy treatment an undifferentiated uterine malignancy with (RT) and/or chemotherapy are often used. characteristics of both carcinoma and sarco- While one study reported that adjuvant RT after ma. The endometrial carcinoma occurs within surgery decreased the risk of pelvic cancer the inner layer of tissue lining of the uterus, recurrence compared to surgery alone [14], it whereas the sarcoma arises from the outer did not provide any overall survival benefit [14]. layer of muscle of the uterus. USC makes up Additional studies have provided evidence to five percent of all uterine cancers [1]. In the support the benefit of aggressive adjuvant che- United States, approximately 2 per 100,000 motherapy that combines RT with DNA damage- women develop UCS annually [2]. Because of based chemotherapy [15-17]. Currently, it the aggressive nature of UCS, only 35% of remains challenging to predict outcomes for patients survive five years after diagnosis. UCS UCS patients and the mechanism underlying and endometrial carcinomas have similar risk patient relapse is unclear. Therefore, a reliable factors. Both malignancies are associated with preoperative biomarker that predicts primary obesity, diabetes, hypertension, smoking, nulli- surgical response and identifies patients who parity, and use of estrogen ortamoxifen [3-9]. would benefit from aggressive adjuvant therapy By contrast, progestin-containing contracep- is urgently needed. URI1 amplification associates with poor prognosis in UCS Table 1. Clinicopathologic characteristics of study reported URI1 amplification in 10% of the overall cohort ovarian cancers and increased URI protein level Characteristic Value correlates with tumor aggressiveness [24]. URI upregulation increases the expression of the Patient size 57 “p53 and DNA damage-regulated gene 1” Age (y) (PDRG1), suggesting a function for URI in DNA Median 68 damage repair [19]. Decreased URI1 expres- Range 51-90 sion inhibits cell proliferation and induces Race apoptosis in ovarian and liver cancer cells [25, White 44 26]. In cervical cancer, increased URI expres- Black 9 sion is also associated with a high tumor grade Asian 3 [27]. Unknown 1 Here, we hypothesize that URI1 amplification is Follow up (days) associated with poor clinical outcome in UCS Median 497 patients. We also reconstituted URI1 upregula- Range 8-3115 tion in a culture cell model and investigated URI Stage overexpression in the DNA damage response. I 22 II 5 Materials and methods III 20 Patient cohort IV 10 Positive pelvic lymph nodes 15 (26%) We analyzed UCS and uterine corpus endome- Positive aortic lymph nodes 9 (16%) trial cacinoma samples with corresponding nor- Tumor recurrence 29 (51%) mal tissue from clinically annotated patients in Surgical margin 12 (21%) The Cancer Genome Atlas (TCGA) Data Portal. Depth of myometrial invasion % All samples met freedom-to-publish criteria Median 40 without restriction or limitations. The uterine Range 0-100 corpus endometrial carcinomas cohort has Residual tumor been reported previously [28]. All UCS patients were postmenopausal (prior bilateral ovariec- R0 34 tomy or >12 months since last menstrual peri- R1 2 od with no prior hysterectomy). All UCS speci- R2 10 mens were surgically resected prior to systemic Rx 11 treatment and all patients received complete Adjuvant treatment surgery as the primary treatment. UCS Patients No 14 did not have metastasis at the time of surgery. Radiation treatment 7 The clinical stage, age at diagnosis, tumor inva- Chemotherapy 17 sion percent, local lymphatic status, and surgi- Radiation+chemo 19 cal margin, were recorded. Patient race, weight, menopausal hormone therapy, hormonal con- traceptives use, tamoxifen use, hypertension, The unconventional prefoldin RPB5 interactor 1 diabetes, full-term pregnancies, and history of (URI1) was originally identified as a scaffold other malignancies were also recorded. protein that binds RNA polymerase II [18]. URI Treatment response, time of disease relapse plays important roles in regulating gene expres- and date of death after initial diagnoses were sion. URI interacts with several transcription recorded after the initial treatment. Lymph factors including transcription factor IIF (TFII), node positivity was determined by H & E stain- and the androgen receptor (AR) in prostate can- ing and immunohistochemistry. We excluded cer cells [19-21]. It also interacts with a chro- patients who received neoadjuvant treatment. matin remodeling complex (PAF1) and transla- We also excluded patients with a history of tion initiation factors [22, 23]. Current clinical tamoxifen use or with colorectal cancer, as findings have shown the correlation between some colon cancers can metastasize to the URI1 and human cancers. For example, one uterus. Using these criteria, we identified 57 2321 Am J Cancer Res 2015;5(7):2320-2329 URI1 amplification associates with poor prognosis in UCS Table 2. URI1 amplification associates with patient pathol- CA), cBioPortal [30], and SPSS version ogy and prognosis 13.0 (SPSS, Inc., Chicago, IL). All in P- vitro experiments were performed URI1 amplification No Yes value three times independently and the Sample size n=34 n=23 error bars represent the standard deviation with significance calculated Age (yrs) 69.2±9.9 70.0±8.4 0.57 by nonparametric t-test. Stage 0.2 I 16 (47%) 6 (26%) Cell survival assay and reagents II 3 (9%) 2 (8%) III 9 (26%) 11 (48%) RL 95-2 cells (ATCC, Manasas, VA), a IV 6 (18%) 4 (17%) uterine/endometrial cancer line, were cultured in DMEM: F12 medium with Primary therapy outcome success1 21 (61%) 10 (43%) 0.18 0.005 mg/ml insulin and 10% FBS. Tumor free survival 14 (41%) 3 (13%) 0.023 Cells were plated in 96-well plates at a Tumor recurrence 18 (53%) 11 (48%) 0.7 concentration of 1,000 cells per well. Days of follow-up 743±206 800±208 0.79 After 48 hours of treatment, cell viabil- Median survival days 771±142 685±198 0.51 ity was measured using the CyQUANT Pelvic lymph nodes 7 (21%) 8 (35%) 0.23 assay (Life Technologies, Waltham, Aortic lymph nodes 5 (15%) 4 (17%) 0.31 MA), as per manufacturer’s instruc- Depth of myometrial invasion %2 33±10.2 55±15.2 0.19 tion. Cisplatin is from Sigma-Aldrich Surgical Margin 5 (15%) 7 (30%) 0.15 (St. Louis, MO). ATM inhibitor is from Selleckchem (Houston, TX) (Catalog 1Defined as complete or partial remission; 2Depth of myometrial invasion divided by depth of myometrial thickness. #S7136). Anti-URI1 antibody is from Santa Cruz Biotechnology (Santa Cruz, CA) (Catalog #376011). Anti-phospho- UCS patients and determined URI1 copy num- ATR (Catalog #2853), phospho-ATM (Catalog ber variation and mRNA expression. #5883), ATM (Catalog #2873), ATR (Catalog #2790), and phospho-γH2AX (Catalog #9718) Statistical analysis antibodies are from Cell Signaling (Berverly, MA). Anti-tubulin antibody (Catalog #489P) is Primary therapy outcome, tumor-free status, from Biolegend (San Diego, CA). new tumor event, and surgical margins between URI1 amplification and control groups were Quantitative reverse transcription-polymerase compared using the chi-square test. The differ- chain reaction (qRT-PCR) ences in age at diagnosis, and follow up time between two groups were evaluated with an qRT-PCR to quantitate ATM mRNA expression unpaired t-test. Tumor stage between control used SYBR Green (Applied Biosystem, Foster and URI1 amplifed groups was evaluated with City, CA). Expression of RPL-19 was used as the the Mann-Whitney test. Spearman’s rank cor- internal control. ATM primers are as following: relation coefficient was used to analyze pair- F: AGACCGCGTGATACTGGATG.
Recommended publications
  • PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday, November 6 41
    American Society of Human Genetics 62nd Annual Meeting November 6–10, 2012 San Francisco, California PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday, November 6 41. Genes Underlying Neurological Disease Room 134 #196–#204 2. 4:30–6:30pm: Plenary Abstract 42. Cancer Genetics III: Common Presentations Hall D #1–#6 Variants Ballroom 104 #205–#213 43. Genetics of Craniofacial and Wednesday, November 7 Musculoskeletal Disorders Room 124 #214–#222 10:30am–12:45 pm: Concurrent Platform Session A (11–19): 44. Tools for Phenotype Analysis Room 132 #223–#231 11. Genetics of Autism Spectrum 45. Therapy of Genetic Disorders Room 130 #232–#240 Disorders Hall D #7–#15 46. Pharmacogenetics: From Discovery 12. New Methods for Big Data Ballroom 103 #16–#24 to Implementation Room 123 #241–#249 13. Cancer Genetics I: Rare Variants Room 135 #25–#33 14. Quantitation and Measurement of Friday, November 9 Regulatory Oversight by the Cell Room 134 #34–#42 8:00am–10:15am: Concurrent Platform Session D (47–55): 15. New Loci for Obesity, Diabetes, and 47. Structural and Regulatory Genomic Related Traits Ballroom 104 #43–#51 Variation Hall D #250–#258 16. Neuromuscular Disease and 48. Neuropsychiatric Disorders Ballroom 103 #259–#267 Deafness Room 124 #52–#60 49. Common Variants, Rare Variants, 17. Chromosomes and Disease Room 132 #61–#69 and Everything in-Between Room 135 #268–#276 18. Prenatal and Perinatal Genetics Room 130 #70–#78 50. Population Genetics Genome-Wide Room 134 #277–#285 19. Vascular and Congenital Heart 51. Endless Forms Most Beautiful: Disease Room 123 #79–#87 Variant Discovery in Genomic Data Ballroom 104 #286–#294 52.
    [Show full text]
  • 1 Introduction + 1.1 Ruvbl1 and Ruvbl2 Are Highly Conserved AAA Proteins
    1. Introduction 1 Introduction + 1.1 RuvBL1 and RuvBL2 are highly conserved AAA proteins RuvBL1 and its homolog RuvBL2 are ubiquitously expressed proteins (Bauer et al. 1998) that belong to the AAA+ family of ATPases (ATPases associated with diverse cellular activities) (Neuwald et al. 1999). This class of ATPases includes nucleic acid processing enzymes, chaperones and proteases. AAA+ proteins often form hexameric ring structures and contain conserved motifs for ATP binding and hydrolysis like the Walker A (GXXXXGKT) and Walker B box (DEXH/N) (Walker et al. 1982), the Arg-finger and sensor residues. All AAA+ proteins use ATP binding and hydrolysis to exert mechanical forces. ATP hydrolysis is clearly essential for the biological activity of RuvBL1 and RuvBL2 (Feng et al. 2003; Jonsson et al. 2004; Wood et al. 2000). RuvBL1 and RuvBL2, consisting of 456 and 463 amino acids respectively, are mainly localised in the nucleus, but also found in the cytosol (Holzmann et al. 1998; Kim et al. 2006; Lim et al. 2000; Salzer et al. 1999). RuvBL2 exhibits 43 % sequence identity and 65 % sequence similarity to RuvBL1. These proteins were originally identified by several unrelated approaches and are therefore known under diverse names (see Table 1). RuvBL1 RuvBL2 Explanation Reference TIP49 TIP48 TATA-binding protein (TBP)-interacting protein (Makino et al. 1998; Wood et al. 2000) TIP49a TIP49b TBP-interacting protein (Kanemaki et al. 1999) Pontin52 Reptin52 repressing Pontin52 (Bauer et al. 2000; Bauer et al. 1998) TAP54α TAP54β TIP60-associated protein (Ikura et al. 2000) TIH1 TIH2 TIP49a/b homolog (Lim et al. 2000) ECP54 ECP51 erythrocyte cytosolic protein (Salzer et al.
    [Show full text]
  • Convergent Regulatory Evolution and Loss of Flight in Paleognathous Birds
    Convergent regulatory evolution and loss of flight in paleognathous birds The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Sackton, Timothy B., Phil Grayson, Alison Cloutier, Zhirui Hu, Jun S. Liu, Nicole E. Wheeler, Paul P. Gardner, et al. 2019. Convergent Regulatory Evolution and Loss of Flight in Paleognathous Birds. Science 364 (6435): 74–78. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:39865637 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#OAP Convergent regulatory evolution and loss of flight in palaeognathous birds Timothy B. Sackton* (1,2), Phil Grayson (2,3), Alison Cloutier (2,3), Zhirui Hu (4), Jun S. Liu (4), Nicole E. Wheeler (5,6), Paul P. Gardner (5,7), Julia A. Clarke (8), Allan J. Baker (9,10), Michele Clamp (1), Scott V. Edwards* (2,3) Affiliations: 1) Informatics Group, Harvard University, Cambridge, USA 2) Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, USA 3) Museum of Comparative Zoology, Harvard University, Cambridge, USA 4) Department of Statistics, Harvard University, Cambridge, USA 5) School of Biological Sciences, University of Canterbury, New Zealand 6) Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK 7) Department of Biochemistry, University of Otago, New Zealand 8) Jackson School of Geosciences, The University of Texas at Austin, Austin, USA 9) Department of Natural History, Royal Ontario Museum, Toronto, Canada 10) Department of Ecology and Evolutionary Biology, University of Toronto, Toronto, Canada *correspondence to: TBS ([email protected]) or SVE ([email protected]) 1 Whether convergent phenotypic evolution is driven by convergent molecular changes, in proteins or regulatory regions, are core questions in evolutionary biology.
    [Show full text]
  • Download 20190410); Fragmentation for 20 S
    ARTICLE https://doi.org/10.1038/s41467-020-17387-y OPEN Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes ✉ Martin Mehnert 1 , Rodolfo Ciuffa1, Fabian Frommelt 1, Federico Uliana1, Audrey van Drogen1, ✉ ✉ Kilian Ruminski1,3, Matthias Gstaiger1 & Ruedi Aebersold 1,2 fi 1234567890():,; Rapidly increasing availability of genomic data and ensuing identi cation of disease asso- ciated mutations allows for an unbiased insight into genetic drivers of disease development. However, determination of molecular mechanisms by which individual genomic changes affect biochemical processes remains a major challenge. Here, we develop a multilayered proteomic workflow to explore how genetic lesions modulate the proteome and are trans- lated into molecular phenotypes. Using this workflow we determine how expression of a panel of disease-associated mutations in the Dyrk2 protein kinase alter the composition, topology and activity of this kinase complex as well as the phosphoproteomic state of the cell. The data show that altered protein-protein interactions caused by the mutations are asso- ciated with topological changes and affected phosphorylation of known cancer driver pro- teins, thus linking Dyrk2 mutations with cancer-related biochemical processes. Overall, we discover multiple mutation-specific functionally relevant changes, thus highlighting the extensive plasticity of molecular responses to genetic lesions. 1 Department of Biology, Institute of Molecular Systems Biology, ETH Zurich,
    [Show full text]
  • Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1 Amplified Ovarian Cancer
    Author Manuscript Published OnlineFirst on September 4, 2013; DOI: 10.1158/1078-0432.CCR-13-1337 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1 amplified ovarian cancer AUTHORS AND AFFILIATIONS Dariush Etemadmoghadam1,2,3, George Au-Yeung1,4, Meaghan Wall5, Chris Mitchell1, Maya Kansara1, Elizabeth Loehrer1, Crisoula Batzios5, Joshy George1,4, Sarah Ftouni1, Barbara A Weir6,7, Scott Carter7, Irma Gresshoff3,8, Linda Mileshkin1,2,9, Danny Rischin1,2,9, William C Hahn6,7, Paul M Waring3,8, Gad Getz7, Carleen Cullinane1,10, Lynda J Campbell5 and David Bowtell1,2,4 1Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; 3Department of Pathology, University of Melbourne, Parkville, Victoria, Australia; 4Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia; 5Victorian Cancer Cytogenetics Service, St Vincent's Hospital, Melbourne, Victoria, Australia; 6Dana-Farber Cancer Institute, Boston, Massachusetts, USA; 7The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA; 8Centre for Translational Pathology, University of Melbourne, Parkville, Victoria, Australia; 9Department of Medicine, University of Melbourne, Parkville, Victoria, Australia; 10Translational Research Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. RUNNING TITLE Resistance to CDK2 inhibitors in CCNE1 amplified cancer KEYWORDS Ovarian Cancer, Resistance, Cyclin E1, CDK inhibitors CORRESPONDING AUTHOR Professor David DL Bowtell Peter MacCallum Cancer Centre [email protected] Page 1 of 22 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2013 American Association for Cancer Research.
    [Show full text]
  • The Landscape of Molecular Chaperones Across Human Tissues Reveals a Layered Architecture of Core and Variable Chaperones
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.976720; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. The landscape of molecular chaperones across human tissues reveals a layered architecture of core and variable chaperones Netta Shemesh1,2+, Juman Jubran1+, Mehtap Abu-Qarn2, Eyal Simonovky1, Omer Basha1, Idan Hekselman1, Shiran Dror2, Ekaterina Vinogradov1, Serena Carra3, Anat Ben-Zvi2* and Esti Yeger-Lotem1* 1 Department of Clinical Biochemistry and Pharmacology and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel 2 Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel 3 Centre for Neuroscience and Nanotechnology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy + These authors contributed equally to this study. * Correspondence to: Prof. Esti Yeger-Lotem, Email: [email protected] Prof. Anat Ben-Zvi, Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.976720; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract The sensitivity of the protein-folding environment to chaperone disruption can be highly tissue-specific.
    [Show full text]
  • Rabbit Anti-C19orf2 Antibody-SL13781R
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-C19orf2 antibody SL13781R Product Name: C19orf2 Chinese Name: 19号染色体开放阅读框2抗体 C19orf2; Chromosome 19 open reading frame 2; NNX3; PPP1R19; Protein NNX3; Protein phosphatase 1 regulatory subunit 19; RMP; RMP_HUMAN; RNA polymerase II subunit 5 mediating protein; RNA polymerase II subunit 5-mediating protein; RPB5 Alias: mediating protein; RPB5-mediating protein; Unconventional prefoldin RPB5 interactor 1; Unconventional prefoldin RPB5 interactor; URI; URI1; URI1, prefoldin-like chaperone. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Pig,Cow,Horse,Rabbit,Sheep, ELISA=1:500-1000IHC-P=1:400-800IHC-F=1:400-800ICC=1:100-500IF=1:100- 500(Paraffin sections need antigen repair) Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 60kDa Cellular localization: The nucleuscytoplasmic Form: Lyophilizedwww.sunlongbiotech.com or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human C19orf2:351-450/535 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. PubMed: PubMed RMP (RPB5-mediating protein), also known as C19orf2, NNX3 or URI, is a 534 amino Product Detail: acid protein that localizes to the nucleus and belongs to the RNA polymerase II subunit 5-mediating protein family.
    [Show full text]
  • DMAP1 Antibody (C-Term) Blocking Peptide Synthetic Peptide Catalog # Bp6136a
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 DMAP1 Antibody (C-term) Blocking Peptide Synthetic peptide Catalog # BP6136a Specification DMAP1 Antibody (C-term) Blocking DMAP1 Antibody (C-term) Blocking Peptide - Peptide - Background Product Information DNA methylation can help to regulate Primary Accession Q9NPF5 transcriptional silencing via repressive Other Accession NP_061973 transcription complexes, which include methyl-CpG-binding domain proteins and histone deacetylases (HDACs) DNMT1, the core DMAP1 Antibody (C-term) Blocking Peptide - Additional Information enzyme for mammalian DNA methylation, can also establish a repressive transcription complex consisting of DNMT1, HDAC2, and a Gene ID 55929 third protein, termed DMAP1 for 'DNMT1-associated protein.' The 467-amino Other Names acid DMAP1 protein shares approximately 98% DNA methyltransferase 1-associated protein amino acid sequence homology with the 1, DNMAP1, DNMT1-associated protein 1, mouse protein. DMAP1 interacts directly with DMAP1, KIAA1425 the N-terminal region of DNMT1, and DMAP1 Target/Specificity can repress transcription independently of The synthetic peptide sequence used to histone deacetylase activity. DNMT1, HDAC2, generate the antibody <a href=/product/pr and DMAP1 form a complex in vivo, and oducts/AP6136a>AP6136a</a> was DMAP1 can interact directly with the selected from the C-term region of human transcriptional corepressor TSG101. The DMAP1 . A 10 to 100 fold molar excess to DNMT1-DMAP1exists throughout the S phase; antibody is recommended. Precise HDAC2 joins DNMT1 and DMAP1 only during conditions should be optimized for a late S phase. This provides a regulated means particular assay. to deacetylate heterochromatin following replication.
    [Show full text]
  • Anti-URI Antibody [SP215] (ARG53704)
    Product datasheet [email protected] ARG53704 Package: 100 μl anti-URI antibody [SP215] Store at: -20°C Summary Product Description Rabbit Monoclonal antibody [SP215] recognizes URI Tested Reactivity Hu Tested Application FACS, IHC-P Host Rabbit Clonality Monoclonal Clone SP215 Isotype IgG Target Name URI Antigen Species Human Immunogen Synthetic peptide derived from the C-terminus of the human URI protein. Conjugation Un-conjugated Alternate Names Protein NNX3; RMP; RNA polymerase II subunit 5-mediating protein; C19orf2; NNX3; URI; RPB5-mediating protein; PPP1R19; Unconventional prefoldin RPB5 interactor 1; Protein phosphatase 1 regulatory subunit 19 Application Instructions Application table Application Dilution FACS Assay-Dependent IHC-P 1:100 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Ovarian Carcinoma Calculated Mw 60 kDa Properties Form Liquid Purification Purified by protein A/G Buffer PBS (pH 7.6), 1% BSA and < 0.1% Sodium azide Preservative < 0.1% Sodium azide Stabilizer 1% BSA Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed www.arigobio.com 1/2 before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Database links GeneID: 8725 Human Swiss-port # O94763 Human Gene Symbol URI1 Gene Full Name URI1, prefoldin-like chaperone Background This gene encodes member of the prefoldin family of molecular chaperones.
    [Show full text]
  • PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday 31 Advances and References in Genomic Technology Room 210 #196–#204 2
    American Society of Human Genetics 63rd Annual Meeting October 22–26, 2013 Boston PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday 31 Advances and References in Genomic Technology Room 210 #196–#204 2. Plenary Abstract Presentations Hall B2 #1–#6 32 Genetic Testing for Neurodevelopmental Disease: Wednesday Genotype: Phenotype Challenges Room 205 #205–#213 2:00pm–4:15pm: Concurrent Platform Session A (10–18): 33 Gene Regulation—At a Multitude of 10. Which Comes First: The Sequence or Levels Room 253 #214–#222 the Biology? Hall B2 #7–#15 34 Cardiovascular Genetics: Exome 11 The Shifting Landscape of Genetic Sequencing and Animal Models Room 258 #223–#231 Testing: Approaches and Success 35 Genomic Medicine: Counseling, Stories Grand Education and Health Services Westin Hotel, Ballroom East #16–#24 Grand 12 Methods in Statistical Genetics Grand Ballroom AB #232–#240 Ballroom West #25–#33 36 Biochemical and Clinical 13 Genetic Variation in Gene Expression Room 210 #34–#42 Consequences of Mitochondrial 14 Cancer Epidemiology: New Loci and Dysfunction Westin Hotel, Methods Room 205 #43–#51 Grand 15 Psychiatric Disease: GWAS to Genes Room 253 #52–#60 Ballroom CDE #241–#249 16 Expanding Knowledge of Mendelian Disorders: Genes, Phenotypes & Friday Treatment Room 258 #61–#69 8:00am–10:15am:oncurrent Platform Session D (45–53): 17 Structural;shCopy Number Variation 45 Mo' Data, Mo' Problems? Hall B2 #250–#258 and Disease Westin Hotel, 46 Cancer Genomics Grand Grand Ballroom East #259–#267 Ballroom AB #70–#78 47 Demography In and Out of
    [Show full text]
  • PDF Output of CLIC (Clustering by Inferred Co-Expression)
    PDF Output of CLIC (clustering by inferred co-expression) Dataset: Num of genes in input gene set: 9 Total number of genes: 16493 CLIC PDF output has three sections: 1) Overview of Co-Expression Modules (CEMs) Heatmap shows pairwise correlations between all genes in the input query gene set. Red lines shows the partition of input genes into CEMs, ordered by CEM strength. Each row shows one gene, and the brightness of squares indicates its correlations with other genes. Gene symbols are shown at left side and on the top of the heatmap. 2) Details of each CEM and its expansion CEM+ Top panel shows the posterior selection probability (dataset weights) for top GEO series datasets. Bottom panel shows the CEM genes (blue rows) as well as expanded CEM+ genes (green rows). Each column is one GEO series dataset, sorted by their posterior probability of being selected. The brightness of squares indicates the gene's correlations with CEM genes in the corresponding dataset. CEM+ includes genes that co-express with CEM genes in high-weight datasets, measured by LLR score. 3) Details of each GEO series dataset and its expression profile: Top panel shows the detailed information (e.g. title, summary) for the GEO series dataset. Bottom panel shows the background distribution and the expression profile for CEM genes in this dataset. Overview of Co-Expression Modules (CEMs) with Dataset Weighting Scale of average Pearson correlations Num of Genes in Query Geneset: 9. Num of CEMs: 1. 0.0 0.2 0.4 0.6 0.8 1.0 Ruvbl1 Ruvbl2 Pfdn2 Skp2 Skp1a Cul1 Uri1 Stap1
    [Show full text]
  • BMC Molecular Biology Biomed Central
    BMC Molecular Biology BioMed Central Research article Open Access Drosophila Uri, a PP1α binding protein, is essential for viability, maintenance of DNA integrity and normal transcriptional activity Jasmin Kirchner†4, Emese Vissi†4, Sascha Gross1,4, Balazs Szoor2,4, Andrey Rudenko3,4, Luke Alphey†4 and Helen White-Cooper*†4 Address: 1Abbott Laboratories, Global Pharmaceutical Regulatory Affairs, Abbott Park, IL 60064-6157, USA, 2Institute of Immunology and Infection Research, University of Edinburgh, EH9 3JT, UK, 3Harvard University, FAS Molecular & Cell Biology, Sherman Fairchild Biochemistry Bldg, 7 Divinity Ave, Cambridge MA, 02138, USA and 4Department of Zoology, University of Oxford, South Parks Rd, Oxford, OX1 3PS. UK Email: Jasmin Kirchner - [email protected]; Emese Vissi - [email protected]; Sascha Gross - [email protected]; Balazs Szoor - [email protected]; Andrey Rudenko - [email protected]; Luke Alphey - [email protected]; Helen White- Cooper* - [email protected] * Corresponding author †Equal contributors Published: 15 April 2008 Received: 9 July 2007 Accepted: 15 April 2008 BMC Molecular Biology 2008, 9:36 doi:10.1186/1471-2199-9-36 This article is available from: http://www.biomedcentral.com/1471-2199/9/36 © 2008 Kirchner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Protein phosphatase 1 (PP1) is involved in diverse cellular processes, and is targeted to substrates via interaction with many different protein binding partners.
    [Show full text]